English

INTERIM REPORT CHRONTECH PHARMA JANUARY-JUNE 2010

Report this content

​

  • Research and development costs amounted to SEK 4.2 (3.1) m
  • The loss after tax was SEK -6.6 (-6.4) m
  • Earnings per share were SEK -0.09 (-0.18)
  • The company had no net sales for the period
  • The patients from the completed ChronVac-C® study are enrolled on treatment according to standard of care, i.e. interferon in combination with ribavirin. As previously reported, of those who started standard of care therapy, >70% have responded to the treatment with <50 virus copies/mL blood already after 4 weeks (so called rapid viral response). This is an unusually rapid reduction of virus in the blood of patients with HCV genotype 1, indicating a role for ChronVac-C® in combination therapy
  • As was made public earlier the multi-center study conducted in Sweden and Norway on ChronSeal® for the treatment of chronic leg wounds is completed. Kringle Pharma, Inc. in Japan has given ChronTech Pharma a six months’ extension, i.e. until the 31st of December 2010, of its option to buy back in ownership of the ChronSeal®

 

Events after the end of the reporting period

  • ChronTech now can report that one week after completed one-week’s treatment with ChronSeal® the healing was significantly better for the two groups receiving active substance as compared to placebo (mean for reduction of wound sizes was 34% and 30%, respectively as compared to -6% for placebo). This gives proof-of-concept for ChronSeal® as treatment of chronic leg wounds

 

 

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28,
E-mail: anders.vahlne@ki.se

  

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se

 

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.

Documents & Links